Oncology

Top news of the week in oncology and cancer drug development.

Checkpoint inhibitors plus myeloid-derived suppressor cell inhibitors show promise as prostate cancer treatment.

Quiescent stem cells are dormant and are not impacted by cancer treatments.

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival in patients with breast cancer.

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival.

New research indicates that high consumption of certain dairy products may either increase or decrease the risk of developing breast cancer, depending on the food.

High yogurt intake may protect against breast cancer, while processed cheeses may increase cancer risk.

Mapping lung cancer cell interactions can unveil new targeted treatment techniques.

Vitamin C observed to kill cancer stem-like cells.

Muscle composition may be predictive of chemotherapy toxicity.

Clinical practice guideline on human papillomavirus (HPV) vaccination can improve prevention of cervical cancer.

Eli Lilly and Company recently announced positive late-stage results in its clinical trial testing a combination of its experimental breast cancer drug and another widely-used treatment.

Cancer-focused continuing education programs seek to enhance cancer care at specialty pharmacies.

The risk of a second cancer remained high even 30 years after treatment.

Progression-free survival with IMMU-132 increases from an average of 3.5 months to 16.6 months in patients with breast cancer.

Top news of the day from across the health care landscape.

Top news of the week in oncology and cancer drug development.

Top news of the day from across the health care landscape.

A combination drug regimen may be the answer to treating acute myeloid leukemia.

Mylan gains global licenses for its biosimilar to trastuzumab (Herceptin).

Senescent cells communication via integrin beta 3 expression.

ATR mutations increase skin cancer tumor growth by modulating the tumor microenvironment.

Improvements in breast cancer patient quality of life and mortality seen over last 30 years.

Patients with small renal masses may be undergo surgery when active surveillance could be beneficial.

Scientists discover a metabolic weakness in advanced breast cancer cells.

High genomic copy loss correlated with metastatic melanoma’s ability to thwart the success of immune checkpoint inhibitors.

Adding pertuzumab (Perjeta) to a breast cancer treatment regimen reduced recurrent disease.

Archival tumor tissue reliably identifies patients with folate receptor alpha-positive ovarian cancer.